Novo Nordisk ADR(NVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 10.89 | EPS (ttm) | 4.09 | Insider Own | 0.01% | Shs Outstand | 3.35B | Perf Week | -1.24% |
| Market Cap | 149.09B | Forward P/E | 13.36 | EPS next Y | -1.99% | Insider Trans | - | Shs Float | 3.35B | Perf Month | -6.64% |
| Enterprise Value | 163.65B | PEG | - | EPS next Q | 0.77 | Inst Own | 9.89% | Short Float | 1.01% | Perf Quarter | 5.62% |
| Income | 18.19B | P/S | 2.9 | EPS this Y | -6.48% | Inst Trans | -0.16% | Short Ratio | 2.86 | Perf Half Y | 15.08% |
| Sales | 51.45B | P/B | 5.82 | EPS next 5Y | -0.06% | ROA | 21.81% | Short Interest | 33.83M | Perf YTD | -12.42% |
| Book/sh | 7.66 | P/C | 21.67 | EPS past 3/5Y | 26.28% 20.36% | ROE | 60.35% | 52W High | -30.55% ($64.16) | Perf Year | -17.94% |
| Cash/sh | 2.06 | P/FCF | 12.64 | Sales past 3/5Y | 23.19% 19.21% | ROIC | 34.67% | 52W Low | 26.88% ($35.12) | Perf 3Y | -54.39% |
| Dividend Est. | $1.82 (4.09%) | EV/EBITDA | 6.17 | EPS Y/Y TTM | 12.68% | Gross Margin | 80.65% | Volatility(W/M) | 2.22% 2.11% | Perf 5Y | -10.24% |
| Dividend TTM | 1.8 | EV/Sales | 3.18 | Sales Y/Y TTM | 13.21% | Oper. Margin | 45.38% | ATR (14) | 1.35 | Perf 10Y | 102.36% |
| Dividend Ex-Date | 2026/8/17 | Quick Ratio | 0.66 | EPS Q/Q | -18.69% | Profit Margin | 35.36% | RSI (14) | 41.34 | Recom | 3.2 |
| Dividend Gr. 3/5Y | 26.98% 19.93% | Current Ratio | 0.87 | Sales Q/Q | 4.59% | SMA20 | -3.62% ($46.23) | Beta | 0.76 | Target Price | $44.5 |
| Payout | 36.87% | Debt/Eq | 0.63 | Earnings | 2026/8/4 | SMA50 | -6.69% ($47.75) | Rel Volume | 0.74 | Prev Close | $45.16 |
| Employees | 68794 | LT Debt/Eq | 0.55 | EPS/Sales Surpr. | 24.09% 11.4% | SMA200 | -3.78% ($46.31) | Avg Volume(3M) | 11.82M | Price | $44.56 |
| IPO | 1981/4/30 | Option/Short | Yes/Yes | Trades | 44393 | Volume | 8,779,486 | Change | -1.33% |
Company
NVO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global leader in the diabetes and obesity treatment market, this pharmaceutical company was founded in Denmark in 1923 and is headquartered near Copenhagen. It holds a top global market share in insulin products and GLP-1-based obesity and diabetes treatments, with a core brand portfolio that includes Wegovy, Ozempic, and Rybelsus.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
NVO has weak earning power
45.38% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -6.5% this year.
Tap to view numbers
The price looks about right
Trading at 10.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -54.4% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 4.09% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 9.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
NVOH 0.97%
EDEN 0.21%
OZEM 0.13%
THNR 0.12%
SOLZ 0.12%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
NVOX 34M NVOH 4M
NVOC -It ranks #4 in the industry
Based on market cap of $149B.
NVO $149B PER 10.9
LLY $1.1T PER 38.2
JNJ $644B PER 31.0
ABBV $443B PER 70.9
실적분석 · 8/5 Novo Nordisk ($NVO) Q2 2026 Earnings Analysis — Adjusted Results and Guidance Raised, Modest After-Hours Rebound 투자 가이드 · 4/11 2026 U.S. High-Dividend Stock Guide — How to Screen Out the Traps 투자 가이드 · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is NVO?
NVO belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of NVO?
The market cap of NVO is approximately $149.1B, ranking 107 within its sector.
Does NVO pay dividends?
NVO has a dividend yield of approximately 4.09%, with an annual dividend of $1.82.
What is the P/E ratio of NVO?
NVO has a P/E ratio of approximately 10.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NVO?
NVO has recorded a 52-week high of $64.16 and a low of $35.12.
